EUCTR2014-002009-40-NL进行中（未招募）1 期
A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel, Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer - MK-3475 vs. paclitaxel, Docetaxel or vinflunine in metastatic urothelial cancer
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 470
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male and Female subjects with recurrent/progressive metastatic urothelial cancer will be enrolled in this trial.
- •1. Be willing and able to provide written informed consent/assent for the trial. The subject may also provide consent/assent for FBR. However, the subject may participate in the main trial without participating in Future Biomedical Research.
- •2. Be =18 years of age on day of signing informed consent.
- •3. Have histologically or cytologically-confirmed diagnosis of urothelial cancer of the renal pelvis, ureter, bladder, or urethra. Both transitional cell and mixed transitional/non-transitional cell histologies are allowed, but transitional cell carcinoma must be the predominant histology. Subjects with non-urothelial cancer of the urinary tract are not allowed.
- •4. Have had progression or recurrence of urothelial cancer following receipt of a first-line platinum-containing regimen (e. g cisplatin, carboplatin):
- •a. Received a first-line platinum-containing regimen in the metastatic setting or for inoperable locally advanced disease
- •b. Received adjuvant platinum-containing therapy following cystectomy for localized muscle-invasive urothelial cancer, with recurrence/progression =12 months following completion of therapy.
- •c. Received neoadjuvant platinum-containing therapy prior to cystectomy for localized muscle-invasive urothelial cancer, with recurrence =12 months following completion of therapy.
- •5. Have received no more than two prior lines of systemic chemotherapy for metastatic urothelial cancer. Subjects for whom the most recent therapy has been a non-platinum-based regimen following progression/recurrence on platinum-based therapy (i.e. third-line patients) are eligible if they have progressed/recurred on their most recent therapy.
- •6. Have provided tissue for biomarker analysis from an archival tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated. A newly-obtained biopsy is strongly preferred but not required if archival tissue is adequate for analysis. Adequacy of the archived or freshly-obtained biopsy specimen must be confirmed by the central laboratory during the screening period prior to enrollment.
- •7. Have measureable disease based on RECIST 1.1 as assessed by the investigator/site radiologist. Tumor lesions situated in a previously irradiated area are considered measureable if progression has been demonstrated in such lesions.
- •8. Have a performance status of 0, 1 or 2 on the ECOG Performance Scale, as assessed within 10 days prior to treatment initiation. Subjects with an ECOG performance status of 2 must have a hemoglobin =10 g/dL, must not have liver metastases, and must have received the last dose of their last prior chemotherapy regimen =3 months (90 days) prior to enrollment.
- •9. Demonstrate adequate organ function as defined in Table 1 of the protocol, all screening labs should be performed within 10 days of treatment initiation
- •10. Female subjects of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- •11. Female subjects of childbearing potential must be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through120 days after the last dose of pembrolizumab or 180 days after the
排除标准
- •1.Has disease that is suitable for local therapy administered with curative intent.
- •2.Currently participating/ has participated in a study of an investigational agent or using an investigational device within 4 weeks prior to the first dose.
- •3.Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose. The use of physiologic doses of corticosteroids may be approved.
- •4.Has had a prior anti-cancer mAb within 4 weeks prior to study Day 1 or who has not recovered (i.e., = Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.
- •5.Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered from adverse events due to a previously administered agent.
- •6.Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer. A history of prostate cancer that was identified incidentally following cystoprostatectomy for bladder cancer is acceptable, provided that the following criteria are met: Stage T2N0M0 or lower; Gleason score = 6, PSA undetectable.
- •7.Has known active CNS metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable, have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.
- •8.Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic or immunosuppressive agents. Subjects with vitiligo, diabetes Type I, or resolved childhood asthma/atopy would be an exception to this rule. Subjects that require intermittent use of bronchodilators, inhaled steroids, or local steroid injections would not be excluded from the study. Subjects with hypothyroidism stable on hormone replacement or Sjøgren’s syndrome will not be excluded from the study.
- •9.Has active cardiac disease, defined as:
- •a. Myocardial infarction or unstable angina pectoris within 6 months of the first date of study therapy
- •b. History of serious ventricular arrhythmia, high-grade AV block, or other cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled); history of QT interval prolongation
- •c. NYHA Class III or greater congestive heart failure, or left ventricular ejection fraction of < 40%
- •10.Has evidence of interstitial lung disease or active non-infectious pneumonitis.
- •11.Has an active infection requiring systemic therapy.
- •12.Has a history of severe hypersensitivity reaction to paclitaxel or to other drugs formulated with polyoxyethylated castor oil, to docetaxel or other drugs formulated with polysorbate 80,or to vinflunine or other vinca alkaloids.
- •13.Requires ongoing therapy with a medication that is a strong inhibitor or inducer of the CYP3A4 enzymes.
- •14.Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject’s participation for the full
研究者
相似试验
进行中（未招募）
1 期
MK-3475 vs. paclitaxel, Docetaxel or vinflunine in metastatic urothelial cancerMetastatic or locally advanced/unresectable urothelial cancer that has recurred or progressed following platinum-based chemotherapy.MedDRA version: 17.1Level: LLTClassification code 10046714Term: Urothelial carcinoma bladderSystem Organ Class: 100000004864EUCTR2014-002009-40-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.470
进行中（未招募）
1 期
MK-3475 vs. paclitaxel, Docetaxel or vinflunine in metastatic urothelial cancerEUCTR2014-002009-40-DKMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.470
已完成
3 期
A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel,Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic UrothelialCancerC67C66Malignant neoplasm of bladderMalignant neoplasm of ureterDRKS00008947Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.542
进行中（未招募）
1 期
MK-3475 vs. paclitaxel, Docetaxel or vinflunine in metastatic urothelial cancerEUCTR2014-002009-40-ATMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.470
进行中（未招募）
1 期
MK-3475 vs. paclitaxel, Docetaxel or vinflunine in metastatic urothelial cancerMetastatic or locally advanced/unresectable urothelial cancer that has recurred or progressed following platinum-based chemotherapyMedDRA version: 20.0Level: LLTClassification code 10046714Term: Urothelial carcinoma bladderSystem Organ Class: 100000004864EUCTR2014-002009-40-HUMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.470